Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02195622 · ClinicalTrials.gov registry record · NA
Randomized Controlled Trial Comparing Two Different Morcellators for HoLEP Procedures
A NA study, sponsored by Indiana Kidney Stone Institute.
- Completed
- Registry status
- NA
- Development phase
- 74
- Enrollment target
NCT02195622 is a NA study that has completed, run by Indiana Kidney Stone Institute. The registered enrollment target is 74 participants.
The verdict
NCT02195622, a NA study, has completed, sponsored by Indiana Kidney Stone Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 74 participants
- Enrollment target
Study Summary
To compare efficiency, in terms of tissue morcellation and removal time, of two commercially available FDA-approved morcellators: the VersaCut and the Piranha in subjects undergoing HoLEP procedure for benign prostatic hyperplasia (BPH).
Interventions
- DEVICE Lumenis VersaCut Morcellator
- DEVICE Wolf Piranha Morcellator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2013-09 |
| Est. Completion | 2016-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02195622
The ClinicalTrials.gov registry entry for NCT02195622 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana Kidney Stone Institute, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lumenis VersaCut Morcellator is the first listed.
NCT02195622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02195622 about?
NCT02195622 is a clinical study titled "Randomized Controlled Trial Comparing Two Different Morcellators for HoLEP Procedures". To compare efficiency, in terms of tissue morcellation and removal time, of two commercially available FDA-approved morcellators: the VersaCut and the Piranha in subjects undergoing HoLEP procedure for benign prostatic hyperplasia (BPH).
What is the current status of trial NCT02195622?
This trial is currently completed. It is a NA study. The enrollment target is 74 participants. The study started on 2013-09. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02195622?
The interventions under investigation include: Lumenis VersaCut Morcellator (DEVICE), Wolf Piranha Morcellator (DEVICE).
Who is sponsoring clinical trial NCT02195622?
This trial is sponsored by Indiana Kidney Stone Institute, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.